Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (formerly Flex Pharma, Inc.) on July 1, 2021. The filing reports on the distribution of warrants to shareholders pursuant to a Merger Agreement dated January 3, 2019. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate action regarding equity instruments.
Material Changes and Corporate Action
The primary event reported is the distribution of warrants to holders of rights issued in July 2019. Key details include:
- Event: Distribution of warrants to satisfy rights obligations.
- Timing: Distribution occurred on or about July 2, 2021.
- Instrument Details: The warrants are exercisable into an aggregate of 142,711 shares of common stock.
- Exercise Price: $15.17 per share.
- Regulatory Basis: Issued under an effective shelf registration statement (Form S-3, No. 333-231010) declared effective on May 17, 2019.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. It is a procedural disclosure regarding the mechanics of the warrant distribution. The text notes that the description of the warrants is qualified by reference to the form of Warrant filed as Exhibit 4.1.
Investor Verification Checklist
- Verify the exact number of warrants received based on individual shareholdings as of July 18, 2019.
- Review the full terms and conditions in the Form of Warrant (Exhibit 4.1) attached to the filing.
- Confirm the exercise price of $15.17 and the total potential share issuance of 142,711 shares.
- Check the final prospectus supplement dated July 1, 2021, for additional issuance details.